What weekly subcutaneous (SQ) testosterone dose is equivalent to a daily 5 mg topical testosterone gel?

Dose Conversion: Topical Gel to Subcutaneous Testosterone

Start with 50 mg subcutaneous testosterone enanthate or cypionate weekly when converting from 5 mg daily topical gel.

Rationale for Dosing

The conversion is not straightforward due to differences in bioavailability between formulations. Topical testosterone gels have approximately 9-14% bioavailability 1, meaning 5 mg daily topical delivers roughly 0.5-0.7 mg of bioavailable testosterone per day (3.5-4.9 mg weekly). However, direct bioavailability calculations don't reliably predict clinical equivalence because of different pharmacokinetic profiles and tissue distribution patterns.

Evidence-Based Starting Dose

The Endocrine Society guidelines recommend 50-100 mg weekly for intramuscular testosterone enanthate or cypionate as standard dosing 2. While these guidelines reference intramuscular administration, recent research demonstrates that subcutaneous testosterone enanthate produces similar steady-state levels to intramuscular formulations, with the advantage of more stable pharmacokinetics 3, 4.

In clinical trials of subcutaneous testosterone enanthate:

• 50 mg weekly achieved mean steady-state testosterone of 422 ng/dL 4
• 75 mg weekly was the most common starting dose, with 92.7% of patients achieving target levels (300-1,100 ng/dL) after dose adjustment 3
• 100 mg weekly produced mean levels of 896 ng/dL 4

Practical Conversion Algorithm

1. Initial dose: 50 mg subcutaneous weekly (conservative starting point)

   • This accounts for the fact that 5 mg daily topical is a relatively low dose (typical gel dosing ranges from 20-100 mg daily 5)

2. Measure trough testosterone at week 6-7 (just before next injection) 6

   • Target mid-normal range: 450-600 ng/dL 6

3. Dose adjustment based on trough levels:

   • If <350 ng/dL: increase to 75 mg weekly
   • If 350-750 ng/dL: continue current dose
   • If >750 ng/dL: decrease to 37.5 mg weekly or consider less frequent dosing

4. Recheck at 12 weeks after any dose adjustment 6

Important Clinical Considerations

Subcutaneous administration offers significant advantages over intramuscular:

• More stable testosterone levels with smaller peak-to-trough fluctuations 3, 7
• Lower estradiol and hematocrit elevations compared to intramuscular cypionate 7
• Virtually painless with >95% of patients reporting no injection-related pain 3
• Can be self-administered with auto-injector devices

Monitoring requirements remain the same regardless of formulation 6:

• Hematocrit at baseline, 3-6 months, then annually (hold if >54%)
• PSA and digital rectal exam per age-appropriate guidelines
• Testosterone levels to guide dosing

Common pitfall: Don't assume equal milligram-to-milligram conversion between topical and injectable formulations. The 5 mg daily topical dose you mention is unusually low—most patients use 50-100 mg daily of gel 5. If your patient was on such a low topical dose, they may have been undertreated, making 50 mg weekly subcutaneous an appropriate or even higher equivalent dose.

Safety note: Subcutaneous testosterone may have a more favorable cardiovascular safety profile than intramuscular formulations due to more physiologic testosterone levels without supraphysiological peaks 5, 7.